Shares of Gilead Sciences, Inc. (GILD) gained 7.3% after the company reported solid results for the second quarter of 2025 ...

Ian "Big E" Berger has been a Miami Dolphins fans for 40 years, but he is fighting a life-threatening liver condition.

The Review by Stefanie Deinhardt-Emmer and colleagues1 on sepsis in patients who are immunocompromised is comprehensive and addresses a key and complex population. However, we would like to express ...

When the liver arrived Ray went down for his transplant in the early hours of the morning. "I said a prayer and me and the ...

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure.

Oral vancomycin is effective in achieving clinical and biochemical remission in paediatric patients with non-primary ...

Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique ...

A tribute to retired Carle Dr. Eugene Greenberg, from a grateful patient he's seen through four transplants over 40 years.

RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative ...

Unexplained itching on hands and feet could signal liver issues. Doctors say, this itching, especially on palms and soles, ...

这项研究标志着PBC治疗进入精准医学时代。通过整合肝硬度检测、早期生化应答评估和新型靶向药物，临床医生可实现三重目标：生化指标正常化、纤维化进展遏制和症状控制。特别是PPAR激动剂的双重作用机制——既改善胆汁酸代谢又缓解症状，为长期困扰患者的瘙痒难题提供解决方案。未来，随着AFFIRM等试验对肝硬化患者数据的补充，治疗策略将更趋完善。